Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Sezary Syndrome 2Recurrence 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1

Interventions

Rituximab 70Cyclophosphamide 46fludarabine 21fludarabine phosphate 20Mycophenolic Acid 20Etoposide 18Whole-Body Irradiation 17Filgrastim 15Radiotherapy 14Antilymphocyte Serum 14Tacrolimus 13Melphalan 13Gemcitabine 13Cyclosporine 13Busulfan 13Methotrexate 12Lenalidomide 12Bortezomib 12Bendamustine Hydrochloride 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Cytarabine 10Doxorubicin 8Dexamethasone 8venetoclax 7thymoglobulin 7pembrolizumab 7Thiotepa 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Non-Hodgkin × Disulfides × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02706405 2022-08-24

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
30 enrolled 29 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡